聚乙二醇-伊立替康对裸鼠人乳腺癌移瘤模型的药效学研究

目的：评价长效拓扑异构酶 Ⅰ 抑制剂聚乙二醇-伊立替康（YP-pegol）的体内抗肿瘤活性。方法：将体外传代培养后的人乳腺癌MCF-7细胞接种到裸鼠右前肢腋部皮下，建立裸鼠人乳腺癌移植瘤模型。待肿瘤体积增长至满足试验要求后，将裸鼠按肿瘤体积随机分为6个组即4个YP-pegol剂量组，1个溶媒对照组和1个阳性对照组。每4天给药1次，共给药3次。每周测量裸鼠体重和瘤体积2~3次。计算出相对肿瘤体积（RTV）、相对肿瘤增殖率（T/C），并使用SPSS 13.0统计软件对各组动物体重、肿瘤体积结果进行统计学处理。疗效评价标准：T/C>40%为无效；T/C≤40%，并经方差分析与阴性对照组比较，P<0.05表示有效并具有统计学意义；用单因素方差分析的方法比较各组动物体重数据，以P<0.05表示有统计学意义；在毒性相当（动物死亡率和体重下降相当）的情况下，对供试品组和阳性对照组的T/C进行比较。结果：YP-pegol各剂量组和阳性对照组的体重均值与溶媒对照组的体重数据均值无显著差异，YP-pegol对裸鼠体重无明显影响；给药后第26天，供试品YP-pegol 20、40、60、90 mg&#183;kg^-1剂量组、阳性对照组（伊立替康，60 mg&#183;kg^-1）与溶媒对照组比较，瘤体积（RTV）明显小于溶媒对照组（P<0.05），并且各治疗组的T/C<40%；与阳性对照组比较，YP-pegol高剂量组（90 mg&#183;kg^-1）肿瘤体积明显低于阳性对照组（P<0.05）。给药后第62天，yp-pegol次高、高剂量组的相对肿瘤体积（rtv）与阳性对照组比较，明显低于阳性对照组（P<0.05）。结论：YP-pegol对裸鼠人乳腺癌移植瘤具有明显的抑瘤作用并呈现一定的量效关系；YP-pegol较注射用伊立替康具有更好的疗效。

Objective: To assess the antitumor activity and safety of the long-acting topoisomerase Ⅰ inhibitor polyethylene glycol-irinotecan(YP-pegol)using nude mice models of xenograft human breast cancer.Methods: The in vitro cultured human breast cancer cell MCF-7 was inoculated into the subcutaneous of the right forelimb axillary in nude mice to establish the xenograft model of human breast cancer.When the tumor volume met the test requirements,the eligible nude mice were randomly assigned to six groups according to the tumor volume:four YP-pegol dose groups(20,40,60,90 mg&#183;kg^-1),a solvent control group and a positive control group(irinotecan 60 mg&#183;kg^-1).The drugs were administered every 4 days for a total of 3 times.The body weight and tumor volume of the mice was measured 2-3 times weekly.The relative tumor volume(RTV)and relative tumor proliferation rate(T/C,%) were calculated according to the formula.Comparing the YP-pegol groups with the solvent control group through the statistical analysis of body weight,RTV and T/C. The body weights and tumor volumes of the six groups were analyzed with SPSS for Windows 13.0 statistical software.Curative effect evaluation standard:if T/C>40%,invalid;if T/C≤40%,and compared with the solvent control group by variance analysis,P<0.05 indicated that the YP-pegol therapy for xenograft tumor mice models was effective and there was statistical significance. The body weight data were compared with single factor analysis of variance,and the P<0.05 indicated that there was statistically significant;if the toxicities were comparable(The mortality and weight decreasing were comparable),then the T/C of the test group was compared with the positive control group.Results: The results of weight decreasing in the 6 groups were comparable,and YP-pegol had no significant effect on the weight changes of the model mice;26 days after the first administration,the YP-pegol groups and the positive control group(irinotecan 60 mg&#183;kg^-1)exhibited significantly lower of RTV than that in solvent control group(P<0.05),all T/C<40%.Compared with the positive control group,RTV was significantly lower in the YP-pegol dose groups(60 and 90 mg&#183;kg^-1 dose group)than that in positive group(P<0.05);62 days after the administration,RTV was significantly lower in the YP-pegol 60 mg&#183;kg^-1 dose group and YP-pegol 90 mg&#183;kg^-1 dose group than that in the positive control group(P<0.05).Conclusion: YP-pegol has significant effects of antitumor on xenograft tumor models with dose-response relationship;YP-pegol has better therapeutic effect than irinotecan injection.

[1] 王伟兰,朱曼,郭代红,等.伊立替康临床应用的安全性研究[J].中国药业,2011,20(3):40 WANG WL,ZHU M,GUO DH,et al.Safety study on clinical application of irinotecan[J].China Pharm,2011,20(3):40
[2] VEERAN GK,GURU VB.Water soluble polymers for pharmaceutical applications[J].Polymers,2011,3(4):1972
[3] HOCH U,STASCHEN CM,JOHNSON RK,et al.Nonclinical pharmacokinetics and activity of etirinotecan pegol(NKTR-102),a long-acting topoisomerase 1 inhibitor,in multiple cancer models[J].Cancer Chemoth Pharmcol,2014,74(6):1125
[4] NAGPAL S,RECHT CK,BERTRAND S,et al.Phase II pilot study of single-agent etirinotecan pegol(NKTR-102)in bevacizumab-resistant high grade glioma[J].J Neurooncol,2015,123(2):227
[5] NAGPAL S,RECHT LD.Etirinotecan pegol DNA topoisomerase 1 inhibitor oncolytic[J].Drug Future,2013,38(4):227
[6] AWADA A,GARCIA A A,CHAN S,et al.Two schedules of etirinotecan pegol(NKTR-102)in patients with previously treated metastatic breast cancer:a randomised phaseⅡ study[J].Lancet Oncol,2013,14(12):1216
[7] 保秋萍,李惠民.肿瘤干细胞的耐药性与耐药机制[J].中国组织工程研究与临床康复,2011,15(1):116 BAO QP,LI HM.Drug resistance and its mechanisms of cancer stem cells[J].J Clin Rehabil Tissue Eng Res,2011,15(1):116
[8] DOYLE LA,ROSS DD.Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2)[J].Oncogene,2003,22(47):7340
[9] AISNER J,MUSANTI R,BEERS S,et al.Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I andⅡ resistance:a pharmacodynamically based phase I trial[J].Clin Cancer Res,2003,9(7):2504
[10] 徐建明.西妥昔单抗单药或与伊立替康联合治疗伊立替康耐药的转移性结直肠癌[J].循证医学,2006,6(5):274 XU JM.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].J Evid Based Med,2006,6(5):274
[11] 王若峥,陈志强,吾甫尔,等.西妥昔单抗联合放化疗治疗中晚期恶性肿瘤[J].中国癌症杂志,2007,17(8):653 WANG RZ,CHEN ZQ,WU PE,et al.Cetuximab plus chemotherapy and/or radiotherapy in the treatment of refractory metastatic cancer[J].Chin Oncol,2007,17(8):653
[12] 林榕波,郭增清,陈奕贵,等.西妥昔单抗联合伊立替康治疗化疗耐药晚期结直肠癌[J].中国癌症杂志,2008,18(1):79 LIN RB,GUO ZQ,CHEN YG,et al.Cetuximab combined with irinotecan in the treatment of chemotherapy-resistant advanced colorectal cancer[J].Chin Oncol,2008,18(1):79
[13] 郑航,陈锦章,廖旺军,等.贝伐单抗联合伊立替康治疗转移性结直肠癌的近期疗效观察[J].南方医科大学学报,2006,26(5):689 ZHENG H,CHEN JZ,LIAO WJ,et al.Efficacy of Avastin in combination with irinotecan for metastatic color ectal cancer[J].J South Med Univ,2006,26(5):689
[14] 胡文蔚,王赫,孙文辉.伊立替康联合氟尿嘧啶亚叶酸钙治疗转移性大肠癌31例临床观察[J].中国癌症杂志,2008,18(1):77 HU WW,WANG H,SUN WH.The 31 cases of clinical observation of irinotecan combined with 5-fluorouracil and leucovorin in treatment of metastatic colorectal cancer[J].Chin Oncol,2008,18(1):77
[15] 王慧娟,闫相涛,路平,等.伊立替康联合顺铂与依托泊苷联合顺铂方案一线治疗广泛期小细胞肺癌的多中心临床研究结果[J].中国癌症杂志,2011,21(10):783 WANG HJ,YAN XT,LU P,et al.Irinotecan plus cisplatin versus etoposide plus cisplatin as the first-line therapy for extensive-disease small cell lung cancer:preliminary results of a multicenter clinical study[J].Chin Oncol,2011,21(10):783